Anthera Pharmaceuticals Inc - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - March 16, 2015

Attached files

file filename
EX-10.34 - EXHIBIT 10.34 - Anthera Pharmaceuticals Incex10_34.htm
EX-10.31 - EXHIBIT 10.31 - Anthera Pharmaceuticals Incex10_31.htm
EX-10.33 - EXHIBIT 10.33 - Anthera Pharmaceuticals Incex10_33.htm
EX-10.23 - EXHIBIT 10.23 - Anthera Pharmaceuticals Incex10_23.htm
EXCEL - IDEA: XBRL DOCUMENT - Anthera Pharmaceuticals IncFinancial_Report.xls
EX-32.1 - EXHIBIT 32.1 - Anthera Pharmaceuticals Incex32_1.htm
EX-32.2 - EXHIBIT 32.2 - Anthera Pharmaceuticals Incex32_2.htm
EX-23.2 - EXHIBIT 23.2 - Anthera Pharmaceuticals Incex23_2.htm
EX-10.36 - EXHIBIT 10.36 - Anthera Pharmaceuticals Incex10_36.htm
EX-10.35 - EXHIBIT 10.35 - Anthera Pharmaceuticals Incex10_35.htm
EX-31.2 - EXHIBIT 31.2 - Anthera Pharmaceuticals Incex31_2.htm
10-K - FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 - Anthera Pharmaceuticals Inca3615010k.htm
EX-31.1 - EXHIBIT 31.1 - Anthera Pharmaceuticals Incex31_1.htm
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 

 
Anthera Pharmaceuticals, Inc.
Hayward, California
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-­3 (No. 333-175095, No. 333-187771 and No. 333-187780) and Form S­-8 (No. 333-165714, No. 333-168970, 333-172100, No. 333-180144 and No. 333-188679 and No. 333-196740) of Anthera Pharmaceuticals, Inc. of our reports dated March 13, 2015, relating to the consolidated financial statements and the effectiveness of Anthera Pharmaceuticals, Inc.’s internal control over financial reporting, which appear in this Form 10-K.
 

 
/s/  BDO USA, LLP

San Jose, California
March 16, 2015
 
 
 

Anthera Pharmaceuticals Inc Reports